Role, Effectiveness, and Outcome of Decompressive Craniectomy for Cerebral Venous and Dural Sinus Thrombosis (CVST): Is Surgery Really an Option?

Mohamed Wael F. Mohamed 1, Su Sandi Aung 2, Nakul Mereddy 3, Sruthi Priyavadhana Ramanan 4, Pousette Hamid 5

1. Neurological Surgery, Royal London Hospital, London, GBR 2. Medicine and Surgery, University of Medicine 1, Yangon, MMR 3. Medicine and Surgery, Bhaskar Medical College, Hyderabad, IND 4. Medicine and Surgery, Saveetha Medical College, Chennai, IND 5. Neurology, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA

Corresponding author: Mohamed Wael F. Mohamed, mw_fadlalla@hotmail.com

Abstract

Cerebral venous and dural sinus thrombosis (CVST) is predominantly a disease of young people. It accounts for 0.5% of all strokes, and patients usually have good outcomes. However, a minority of patients may present with elevated intracranial pressure characteristics in a serious illness type and may die from brain herniation if not treated promptly. Decompressive craniectomy (DC) is the only treatment modality that can prevent death in such cases of imminent brain herniation. Unfortunately, due to the condition’s rarity and ethical concerns, randomized controlled trials are not available. This review assessed the available literature on cerebral venous and dural sinus thrombosis in different age groups and decompressive craniectomy in cerebral venous and dural sinus thrombosis. It revealed that decompressive surgery is extremely effective when done early and for the correct indications with patients achieving excellent functional outcomes post-surgery. Decompressive surgery is recommended in rapidly deteriorating patients with computed tomography (CT) scan evidence of basal cisterns effacement, a mass effect from haemorrhage and/or infarction, and significant midline shift.

Introduction And Background

The occlusion or thrombosis of the cerebral and/or dural sinuses is called cerebral venous and dural sinus thrombosis (CVST). It is considered a rare form of stroke, comprising 0.5%-1.0% of all strokes [1]. CVST primarily affects neonates and young persons, with a median age of 37 years at diagnosis. The ratio of female: male is 3:1, and the women affected appear to be younger than men [2]. Gender-specific risk factors, such as oral contraceptive pills (OCP), pregnancy, and puerperium, may be associated with the larger number of women affected [3]. CVST can occur in any of the cerebral veins or sinuses. Nevertheless, the most frequently affected location is the superior sagittal sinus, followed by the transverse sinus and other cortical and deep brain vessels [2].

The International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) was a large, multinational, multicentre, prospective, observational study that enrolled 624 adult patients with CVST from 1998 - 2001. The study identified multiple risk factors and presentation modes, and headache was identified as the most frequent complaint (Table 1) [2].
| Risk factors                                      |
|-------------------------------------------------|
| None identified                                  |
| Thrombophilia                                    |
| Genetic ([Leiden mutation, Prothrombin polymorphism, Protein C deficiency, Protein S deficiency, Plasminogen deficiency, Factor V G1691A mutation, Factor II G20210A variant]) |
| Acquired ([Antiphospholipid antibody, Nephrotic syndrome, Hyperhomocystinaemia]) |
| Malignancy ([CNS, Solid tumour outside CNS, Haematological]) |
| CNS disorders ([Dural fistulae, Venous anomaly, AVM]) |
| Haematological conditions ([Polycythaemia, Thrombocytopenia, Anaemia]) |
| Vasculitis ([SLE, Bechet disease, RA, Thrombangitis obliterans]) |
| Inflammatory disorders ([Intestinal inflammatory disease, Sarcoïdosis]) |
| Thyroid disease                                  |
| Pregnancy and Puerperium                         |
| Infection ([CNS, Sinus, Mouth, Face, and Neck])   |
| Mechanical ([Lumbar puncture, Cranial trauma, Jugular catheter occlusion, Neurosurgery]) |
| Drugs ([Oral contraceptive pills, Hormone replacement, Steroids, Cytotoxic, and others]) |
| Surgery                                          |
| Dehydration                                      |
| Symptoms and signs                               |
| Headache                                         |
| Visual loss                                      |
| Papilledema                                      |
| Diplopia                                         |
| Stupor or coma                                   |
| Aphasia                                          |
| Mental status disorder                           |
| Paresis                                          |
| Bilateral motor signs                            |
| Seizure                                          |
| Sensory symptoms                                 |
| Focal cortical signs                             |
| Fever                                            |
| Concentration impairment                         |

**TABLE 1: Risk factor, symptoms, and signs of CVST**

CVST: cerebral venous and dural sinus thrombosis; CNS: central nervous system; AVM: arteriovenous malformation; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis

The European Stroke Organization has guidelines for the diagnosis and management of cerebral venous and...
dural sinus thrombosis (CVST). CVST is diagnosed by demonstrating the presence of thrombus by neuroimaging. The principal modalities used to diagnose CVST in suspected patients are computed tomography venogram (CTV) and magnetic resonance venogram (MRV) [4].

Management depends on the patient’s clinical profile. Anticoagulation, endovascular intervention, and surgery are included in the treatment modalities. The key therapy is anticoagulation with heparin. Moreover, any other disorders, such as seizures, should be dealt with. A minority of patients will rapidly deteriorate due to raised intracranial pressure (ICP), leading to imminent brain herniation. This is termed malignant CVST, and in these patients, decompressive craniectomy (DC) is lifesaving [4-5].

Review
Medical management
The main treatment of CVST in the acute phase comprises anticoagulation either with dose-adjusted intravenous unfractionated heparin or weight-adjusted subcutaneous low molecular weight heparin (LMWH) for three to 12 months, depending on aetiology. Low molecular weight heparin (LMWH) is preferable to unfractionated heparin. Anticoagulation should be started even in the presence of intracranial haemorrhage. Also, adequate rehydration is of utmost importance as dehydration can worsen the hypercoagulability state. Simultaneously, the management of underlying aetiology should be commenced if possible [4,6].

Patients who deteriorate might require intra-arterial/endovascular thrombolysis, thrombectomy, or a combination of both, but more research needs to be done in this field to determine future treatment plans. Furthermore, intracranial pressure (ICP) management is critical and should commence early and extend post-surgery if need be [4,7-10].

Decompressive craniectomy technique and rationale
Decompressive craniectomy (DC) is the surgical procedure that involves removing part of the skull, including either a frontotemporoparietal bone flap of at least 15 cm in length and extending into the temporal floor with the opening of the dura with or without a synthetic dural replacement or a bifrontal (bicoronal) bone flap in terms of more diffuse swelling. This provides enough space for the brain to expand beyond the confines of the skull. The bone removal combined with resection of infarcted cerebral tissue is termed internal decompression instead of external decompression, which only involves removing the bone and duroplasty.

The inability of venous outflow to match arterial inflow results in venous congestion. Due to the skull’s rigid nature, cerebral oedema’s escalation leads to increased intracranial pressure (ICP), which reduces cerebral perfusion pressure (CPP), cerebral blood flow (CBF), and oxygenation [11]. Although medical management is usually the first line in managing CVST, patients presenting with malignant CVST might not benefit from medical treatment alone. Such treatment cannot prevent brain herniation. DC removes the immediate threat of herniation, improves cortical collateral venous drainage leading to a reduction in intracranial pressure, and improves regional cerebral oxygen saturation and, generally, CVST patients who undergo DC do better than ischemic stroke patients as the main pathology is oedema rather than ischemia and their brains can recover completely [12-14].

In a study conducted by Keller et al., DC indications in CVST patients included rapid deterioration in the level of consciousness accompanied with CT findings of oedema, venous infarction, and congestional haemorrhage with mass effect, significant midline shift, and obliteration of basal cisterns [15].

DC’s role in the care of traumatic brain injury and ischemic arterial stroke management is well-supported [16-17]. Compared to this, research in DC due to CVST is limited, mainly due to the rarity of the condition and ethical concerns in conducting randomized controlled trials. Nonetheless, the number of studies evaluating the role of DC in CVST has increased. From 2000 to 2004, 15 patients with CVST were assessed in a prospective study in Switzerland. Just four patients had DC. Two patients had external decompression, and two had internal decompression. All four patients had a favourable outcome (Glasgow outcome score 4 and 5) [15]. Another prospective study in Amsterdam from 2006 to 2011 included 10 patients who underwent DC among 56 CVST patients. Five patients had recovered completely (modified Rankin score 0-1), two patients suffered from residual disabilities (modified Rankin score 2-3), one patient severely disabled (modified Rankin score 5), and only two patients died (modified Rankin score 6) [18].

Due to the rarity of the disease, most of the literature reports are small retrospective studies. However, at least, the patterns in how patients did will help guide patient care and future studies. Alarming findings were reported in a retrospective study comparing results between patients treated only medically (n=23) and those who had DC following medical management’s failure. Compared with eight patients who died in the surgical group, all patients who were only treated medically died (23% vs. 100%, p<0.001) [19]. Similarly, Mohindra et al. retrospectively studied the outcome in 13 patients who had DC following the failure of medical treatment or malignant CVST and impending herniation. Only two patients died, and both had a low Glasgow Coma Scale (GCS) score before surgery (GCS<5). The survivors were followed up (median 35
Cerebral venous and dural sinus thrombosis (CVST) affects women before, during pregnancy, and in the heterozygosity for the G20210A mutation in factor II administration of anticoagulation before relapse, persistent occlusion on repeat imaging, and correction as required leads to favourable outcomes once they occur. Treatment with anticoagulation and hydration, antibiotics, and anaemia complications according to the underlying prothrombotic risk factors. The incidence of CVST in children is multifactorial. Heller et al. found that 56% of patients had at least one prothrombotic risk factor relative to the control group. Furthermore, 70.5% of CVST diagnosed patients had an underlying predisposing disorder. In conjunction with an underlying condition, the prothrombotic risk factor was independently associated with CVST development in children. According to a registry in Canada involving 16 pediatric centres, the incidence of cerebral venous and dural sinus thrombosis (CVST) patients who have undergone decompressive craniectomy (DC). In a study of 15 patients with CVST, Keller et al. reported four patients who underwent DC. In all four patients, anticoagulation was initiated 12 hours after surgery with half the therapeutic dosage, and 24 hours post-surgery, patients received the full anticoagulation dose. In this study, no patients suffered from the expansion of existing haemorrhages or other complications associated with bleeding. The decision to restart anticoagulation should be tailored to the patient, and anticoagulation can be deferred for days in some cases if it is deemed to be safer for the patient. The decision to restart anticoagulation depends heavily on the managing team's experience and weighing the benefit of preventing thrombus propagation against the risk of bleeding.

Timing of anticoagulation after DC
There are currently no guidelines on the timing of reinstatement of anticoagulation in cerebral venous and dural sinus thrombosis (CVST) patients who have undergone decompressive craniectomy (DC). The aetiology that contributes to CVST development in children is multifactorial. Heller et al. found that 56% of patients had at least one prothrombotic risk factor relative to the control group. Furthermore, 70.5% of CVST diagnosed patients had an underlying predisposing disorder. In conjunction with an underlying condition, the prothrombotic risk factor was independently associated with CVST development in children. According to a registry in Canada involving 16 pediatric centres, the incidence of cerebral venous and dural sinus thrombosis (CVST) patients who have undergone decompressive craniectomy (DC). In a study of 15 patients with CVST, Keller et al. reported four patients who underwent DC. In all four patients, anticoagulation was initiated 12 hours after surgery with half the therapeutic dosage, and 24 hours post-surgery, patients received the full anticoagulation dose. In this study, no patients suffered from the expansion of existing haemorrhages or other complications associated with bleeding. The decision to restart anticoagulation should be tailored to the patient, and anticoagulation can be deferred for days in some cases if it is deemed to be safer for the patient. The decision to restart anticoagulation depends heavily on the managing team's experience and weighing the benefit of preventing thrombus propagation against the risk of bleeding.

CVST in the elderly
A total of 624 adult patients with cerebral venous and dural sinus thrombosis (CVST) were enrolled and followed-up for a median duration of 16 months. Fifty-one patients (8.2%) were aged 65 years or greater. In older patients, the occurrence of isolated intracranial hypertension syndrome was less common (4/51 vs. 139/573, p=0.008) while decreased awareness (17 vs. 97, p=0.005) and changes in mental state (22 vs. 115, p=0.001) were more frequent in elderly patients. The differential diagnosis in the elderly is expansive. Therefore, physicians should have a high index of suspicion in elderly patients to avoid missing the diagnosis of CVST in this age group, as depressed awareness and mental status changes are a relatively common presentation.

The prognosis of elderly patients was significantly worse than that of younger patients, as only 49% of elderly patients had full recovery (compared to 82% in younger patients). In comparison, 27% died and 22% were dependant at the end of follow-up (compared with 7% and 2% of younger patients, respectively). Carcinoma (5 cases) was more common in elderly patients (p=0.017) as a risk factor for CVST. Furthermore, elderly patients were more likely to experience thrombotic incidents during follow-up (HR 4.8, 95% CI=1.9 - 11.9) and were less likely to have a severe headache (HR=0.2, 95% CI=0.02, 0.97).

Timing of anticoagulation after DC
There are currently no guidelines on the timing of reinstatement of anticoagulation in cerebral venous and dural sinus thrombosis (CVST) patients who have undergone decompressive craniectomy (DC). The aetiology that contributes to CVST development in children is multifactorial. Heller et al. found that 56% of patients had at least one prothrombotic risk factor relative to the control group. Furthermore, 70.5% of CVST diagnosed patients had an underlying predisposing disorder. In conjunction with an underlying condition, the prothrombotic risk factor was independently associated with CVST development in children. According to a registry in Canada involving 16 pediatric centres, the incidence of cerebral venous and dural sinus thrombosis (CVST) patients who have undergone decompressive craniectomy (DC). In a study of 15 patients with CVST, Keller et al. reported four patients who underwent DC. In all four patients, anticoagulation was initiated 12 hours after surgery with half the therapeutic dosage, and 24 hours post-surgery, patients received the full anticoagulation dose. In this study, no patients suffered from the expansion of existing haemorrhages or other complications associated with bleeding. The decision to restart anticoagulation should be tailored to the patient, and anticoagulation can be deferred for days in some cases if it is deemed to be safer for the patient. The decision to restart anticoagulation depends heavily on the managing team's experience and weighing the benefit of preventing thrombus propagation against the risk of bleeding.

CVST in paediatrics
According to a registry in Canada involving 16 pediatric centres, the incidence of cerebral venous and dural sinus thrombosis (CVST) in pediatric patients was found to be 0.67 patients per 100,000. The most frequently affected age group was the neonates; most (53%) were anticoagulated and only 8% died. In another retrospective study of 54 patients from 2006 to 2008, Thanga et al. reported a mortality rate of 17.7%. However, the duration of coma or time between deterioration and surgery was not statistically associated with poor outcomes, contradicting other studies. Other retrospective studies demonstrate the trend of excellent functional outcomes and low mortality rates. Similarly, three case reports showed favourable outcomes even in patients who present with fixed and dilated pupils. Delay in presentation or surgery resulted in poorer outcomes.

CVST in women
Cerebral venous and dural sinus thrombosis (CVST) affects women before, during pregnancy, and in the
puerperal period, so early detection and management improve women’s outcomes and their newborn children. In women, contraceptive use, pregnancy, and puerperium are the major risk factors [35].

The ISCVT data were utilized by Coutinho et al., and gender discrepancies were evaluated. Of the 624 patients who were included in the ISCVT, 465 (75%) were female. Women usually had a more chronic presentation, less time between symptoms and admission, and a shorter hospital stay relative to their male counterparts. Besides, women were more likely to recover completely (75%) than men (71%) (p=0.01). The study also showed that most women (65%) had a gender-specific risk factor for CVST and appeared to have more favourable outcomes relative to CVST diagnosed in women without such risk factors [3].

No clear guidance is available regarding the treatment of CVST in women during pregnancy and puerperium, and a limited number of studies guide treatment decisions. A systematic review by Kashkoush et al. on CVST in pregnancy and puerperium with a mean follow-up period of 5.9 months included 66 patients. Treatment options utilized were anticoagulation in 91%, intra-arterial thrombolysis alone in 26%, and thrombectomy and thrombolysis in 8%. Ninety-four per cent (94%) had excellent outcomes, and a combination of thrombolysis and thrombectomy showed a better outcome (p=0.01) [8]. More research is needed to establish future management strategies. Likewise, the role of DC in pregnant and puerperal women is not well-defined. However, for patients presenting with a severe form of CVST during pregnancy or puerperal period, decompressive craniectomy (DC) is lifesaving with favourable functional outcomes [36-39].

The recurrence rate of CVST and extracerebral thrombosis during subsequent pregnancies is low (6%), and the outcome is rarely adverse. Therefore, women with a previous history of CVST should be informed that subsequent pregnancies are not discouraged and should be counselled about the risks of oral contraceptive pills [4,40-41].

### Outcome

The overall outcome of CVST is good, even among patients admitted to the intensive care unit with an annual mortality rate of 2.5% and in-hospital mortality of 2%. Excellent recanalization rates are seen in most treated patients with low recurrence rates [42-44]. The ISCVT had a median follow-up of 16 months, and at the end of follow-up, 70% had a complete recovery and death or dependency occurred in 13.4%. Predictors for poor outcome and death were age greater than 37 years (hazard ratio [HR] 2.0), male sex (HR 1.6), coma (HR 2.7), mental status disorder (HR 2.0), haemorrhage on admission CT scan (HR 1.9), thrombosis of the deep cerebral venous system (HR 2.9), central nervous system infection (HR 3.5), and cancer (HR 2.9). In terms of recurrence, 14 patients (2.2%) had a recurrent sinus thrombosis, 27 (4.3%) had other thrombotic events, and 66 (10.6%) had seizures [2]. Due to the small number of patients undergoing DC, the ISCVT study did not assess the outcome in this subgroup of patients. This was studied by the same investigators seven years after the ISCVT results were published. Ferro et al. published a systematic review of all patients treated with decompressive craniectomy (DC). Sixty-nine (69) patients were included, and 38 were from the registry. At last follow-up (median, 12 months), only 12 (17.4%) had an unfavourable outcome and 11 (15.9%) died [45]. In a retrospective cohort study in Utah, 68 patients (76.4%) had a good outcome (modified Rankin score 2), and 21 (23.6%) had a poor outcome (modified Rankin score >2). Infection (p=0.02) and interestingly decompressive surgery (p=0.02) were associated with poor outcomes [46]. The disease’s severe nature might explain this in those patients requiring surgical intervention, also delayed diagnosis, and/or in-hospital complications that might have played a role [5,35,47-49].

Although the majority of patients usually recover from CVST and have normal neuropsychiatric evaluation [15]. Some of the survivors suffer from psychosocial impairments that can impair their personal and professional lives [50]. Therefore, long-term follow-up and appropriate support should be provided to inflicted patients.

Table 2 lists some studies on DC with CVST.
| Author and year of publication | Design | Study period | Country | Number of patients who underwent DC | Indication for DC | Mean follow-up duration (months) | Result | Comments |
|--------------------------------|--------|--------------|---------|-------------------------------------|------------------|-------------------------------|--------|----------|
| Lath et al. 2010 [5]           | Retrospective single-centre | 2003 - 2009 | India   | 11                                  | Clinical deterioration and herniation syndrome | 6                  | 8 patients had a favourable outcome, and 3 patients died. Recommended DC |
| Mohindra et al. 2011 [20]      | Retrospective single-centre | 2004 - 2009 | India   | 13                                  | Malignant CVST    | 39                             | All patients had a favourable outcome. Recommended DC |
| Ferro et al. 2011 [45]         | Systematic review multi-centre registry | 1998 - 2010 | multiple | 45                                  | Poor GCS and significant hemispheric lesion | 14.5               | 39 patients had a favourable outcome, and 11 patients died Recommended DC |
| Vivakaran et al. 2012 [22]     | Retrospective single-centre study | 2006 - 2008 | India   | 34                                  | Clinical deterioration; herniation syndrome | 11.7               | 14 patients had a favourable outcome, and 4 patients died Recommended DC |
| Zuurbier et al. 2012 [18]      | Prospective single-centre | 2006 - 2010 | Netherlands | 10                                | Poor GCS and expanding hemorrhagic infarct | 12                  | 7 patients had a favourable outcome, 1 was severely disabled, and 2 died. Recommended DC |
| Aaron et al. 2013 [21]         | Retrospective single-centre study | 2002 - 2011 | India   | 44                                  | The volume of lesion and midline shift | 25.5               | 27 patients had a favourable outcome, 9 patients died, and 3 lost to follow-up. Recommended DC |
| Soyer et al. 2016 [44]         | Retrospective single-centre study | 2002 - 2005 | France  | 16                                  | Clinical deterioration | 28                  | 5 patients died. For a similar CVST severity, craniectomy did not improve the outcome. |
| Zhang et al. 2017 [24]         | Retrospective single-centre | 2005 - 2015 | China   | 58                                  | Clinical deterioration and herniation syndrome | 6                  | 33 patients had a favourable outcome, and 8 died. Recommended DC |
| Venkateswaran et al. 2018 [13] | Prospective cohort study | 2005 - 2015 | India   | 17                                  | Clinical deterioration and midline shift | 18.6               | 14 patients had a favourable outcome, 1 patient died, and 2 lost to follow-up. Improvement in regional cerebral oxygen saturation with DC |

**TABLE 2: Studies on decompressive craniectomy with CVST (a minimum of 10 patients and those who were followed up were included)**

GCS: Glasgow Coma Scale; CVST: cerebral venous and dural sinus thrombosis; DC: decompressive craniectomy

**Limitations**

The literature review search included only published studies in the English language from 1999 onwards. Therefore, it does not reflect all published literature on the topic. Similarly, PubMed and PubMed Central were the only two research sources, which might have reduced the number of reviewed articles.
Conclusions
CVST is generally associated with good overall survival and functional recovery. Still, a minority of patients can suffer from devastating functional outcomes and even die due to raised intracranial pressure and brain herniation. DC should be performed in a timely fashion in CVST patients who rapidly deteriorate and have CT evidence of a midline shift greater than 5 mm, effacement of basal cisterns, and significant mass effect. The available studies in the literature demonstrate excellent functional outcomes in CVST patients who had DC.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Bousser MG, Ferro JM: Cerebral venous thrombosis: an update. Lancet Neurol. 2007, 6:162-170. 10.1016/S1474-4422(07)70029-7
2. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators: Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004, 35:664-670. 10.1161/01.STR.0000117571.7697.26
3. Coutinho JM, Ferro M, Canhão P, Barinagarrementeria F, Cantú C, Bousser MG, Stam J: Cerebral veins and sinus thrombosis in women. Stroke. 2009, 40:2356-2361. 10.1161/STROKEAHA.108.543884
4. Ferro JM, Bousser MG, Canhão P, et al.: European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol. 2017, 24:1205-1215. 10.1111/ene.13381
5. Lath R, Kumar S, Reddy R, Boola GR, Ray A, Prabhakar S, Ranjan A: Decompressive surgery for severe cerebral venous sinus thrombosis. Neurol India. 2010, 58:592-597. 10.4103/0028-3886.65923
6. Ghandehari K, Riasi HR, Nouredinne A, et al.: Safety assessment of anticoagulation therapy in patients with hemorrhagic cerebral venous thrombosis. Iran J Neurol. 2015, 12:87-91.
7. Siddiqui FM, Dandapat S, Banerjee C, Zaurbier SM, Johnson M, Stam J, Coutinho JM: Mechanical thrombectomy in cerebral venous thrombosis: systematic review of 185 cases. Stroke. 2015, 46:1263-1268. 10.1161/STROKEAHA.114.007465
8. Kashkoush AI, Ma H, Agarwal N, et al.: Cerebral venous sinus thrombosis in pregnancy and puerperium: a pooled, systematic review. J Clin Neurosci. 2017, 39:9-15. 10.1016/j.jocn.2017.02.046
9. Coutinho JM, Ferro M, Zaurbier SM, et al.: Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. Int J Stroke. 2015, 10:135-140. 10.1111/ijst.12761
10. Poulsen FR, Hegedal L, Stilling MV, Birkeland PF, Schultz MK, Rasmussen JN: Good clinical outcome after combined endovascular and neurosurgical treatment of cerebral venous sinus thrombosis. Dan Med J. 2013, 60:4724.
11. Wilson MH: Monro-Kellie 2.0: the dynamic vascular and venous pathophysiological components of intracranial pressure. J Cereb Blood Flow Metab. 2016, 36:1358-1350. 10.1177/0271263816648711
12. Mahale R, Mehta A, Varma RG, Hegde AS, Acharya PT, Srinivasa R: Decompressive surgery in malignant cerebral venous sinus thrombosis: what predicts its outcome? J Thromb Thrombolysis. 2017, 43:530-539. 10.1007/s11239-017-1489-x
13. Venkateswaran P, Srignesh K, Chakrabarti D, Srinivas DB, Rao GSU: Regional cerebral oxygen saturation changes after decompressive craniectomy for malignant cerebral venous thrombosis: a prospective cohort study. J Neurosurg Anesthesiol. 2019, 31:244-246. 10.1097/ANA.0000000000000498
14. Lövblad KO, Bassetti C, Schneider J, Guzman R, Remondi L, Schroth G: Diffusion-weighted MR in cerebral venous thrombosis. Cerebrovasc Dis. 2001, 11:169-176. 10.1159/000047634
15. Keller E, Pangulu A, Fandino J, Koni D, Yonekawa Y: Decompressive craniectomy in severe cerebral venous and dural sinus thrombosis. Acta Neurochir Suppl. 2005, 94:177-183. 10.1007/s00723-005-1279-1
16. Hutchinson PJ, Kolias AG, Tajic T, et al.: Consensus statement from the International Consensus Meeting on the role of decompressive craniectomy in the management of traumatic brain injury. Acta Neurochir (Wien). 2019, 161:1261-1274. 10.1007/s00701-019-03596-y
17. Vahey K, Hofmeijer J, Jettelt E, et al.: Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007, 6:215-222. 10.1016/S1474-4422(07)70036-4
18. Zaurbier SM, Coutinho JM, Majoie CB, Coert BA, van den Munckhof P, Stam J: Decompressive hemicraniectomy in severe cerebral venous thrombosis: a prospective case series. J Neurosurg. 2012, 259:1099-1105. 10.1093/jn/2014-011-6307-3
19. Baharvahdat H, Ahmadi S, Ganjeifar B, et al.: Malignant cerebral venous infarction: decompressive craniectomy versus medical treatment. World Neurosurg. 2019, 128:918-922. 10.1016/j.wneu.2019.05.028
20. Mohindra S, Umredkar A, Singha N, Bal A, Gupta SK: Decompressive craniectomy for malignant cerebral oedema of cortical venous thrombosis: an analysis of 15 patients. Br J Neurosurg. 2011 Jun, 25:422-9. 10.1017/S0268869711758775
21. Aaron S, Alexander M, Moothy RK, et al.: Decompressive craniectomy in cerebral venous thrombosis: a
single centre experience. J Neurol Neurosurg Psychiatry. 2013, 84:995-1000. 10.1136/jnnp-2012-303356

22. Rajan Vivakaran TT, Srinivas D, Kulkarni GB, Somanna S: The role of decompressive craniectomy in cerebral venous sinus thrombosis. J Neurol Neurosurg Psychiatry. 2012, 117:738-744. 10.1136/jnnp-2012-301112

23. Mousain M, Crassard J, Bresson D, et al.: Should decompressive surgery be performed in malignant cerebral venous sinus thrombosis? A series of 12 patients. Stroke. 2010, 41:727-731. 10.1161/STROKEAHA.109.572909

24. Zhang S, Zhao H, Li H, You C, Hui X: Decompressive craniectomy in hemorhagic cerebral venous thrombosis: clinicoradiological features and risk factors. J Neurol. 2017, 127:709-715. 10.3171/2016.8.JNS11112

25. Koopman K, Uyttenboogaart M, Vroomen PC, van der Meer J, De Keyser J, Luijckx GJ: Cerebral vein and dural sinus thrombosis during subsequent pregnancy and puerperium. J Stroke. 2017, 48:321-326. 10.1161/STROKEAHA.116.015294

26. Lanterna LA, Gritti P, Manara O, Grinod G, Bortolotti G, Birolli F: Decompressive surgery in malignant dural sinus thrombosis: report of 3 cases and review of the literature. Neurosurg Focus. 2009, 26:5. 10.3171/2009.3.FOCUS09010

27. Pizzi MA, Alejos DA, Siegel JL, Kim BY, Miller DA, Freeman WD: Cerebral venous thrombosis associated with intracranial hemorrhage and timing of anticoagulation after hemicraniectomy. J Stroke Cerebrovasc Dis. 2016, 25:2313-2316. 10.1016/j.stjced.2016.05.025

28. Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F, ISCVT Investigators: Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005, 36:1927-1952. 10.1161/01.STR.0000178994.05495.54

29. deVeber G, Andrew M, Adams C, et al.: Cerebral sinovenous thrombosis in children. N Engl J Med. 2001, 9:417-423. 10.1056/NEJM200108093450604

30. Héctor C, Heinecke A, Junker R, et al.: Cerebral venous thrombosis in children: a multifactorial origin. J Pediatr. 2005, 146:1562-1567. 10.1016/j.jpeds.2004.09.0513

31. Javed I, Sultan T, Behram ZU, Yaseen MR: Clinical spectrum and outcome of cerebral venous sinus thrombosis in children. J Coll Physicians Surg Pak. 2018, 28:390-395.

32. Kenet G, Kirkham F, Niederstadt T, et al.: Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol. 2007, 6:595-603. 10.1016/S1474-4422(07)70131-X

33. Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ, et al.: Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: the RENAMEVASC study. J Stroke Cerebrovasc Dis. 2012, 21:395-400. 10.1016/j.jstrokecerebrovasdis.2011.01.001

34. Elke M, Jürgens KU, Tomandl B, Merten U, Kastrup A: Surgical treatment of space occupying edema and hemorrhage due to cerebral venous thrombosis during pregnancy. Neurocrit Care. 2011, 15:166-169. 10.1007/s12028-010-9389-3

35. Gioiti I, Faropoulos K, Picolas C, Lambrou MA: Decompressive craniectomy in cerebral venous sinus thrombosis during pregnancy: a case report. Acta Neurochir (Wien). 2019, 161:1349-1352. 10.1007/s00701-019-03591-5

36. Sorianno-Navarro E, Cano-Negrova V, Menéndez-Manjarrez F, Farington-Terrero E, Méndez-Gallardo JJ, García-Irigoyen A, Arauz E: Bilateral decompressive craniectomy in malignant cerebral venous thrombosis. J Case Rep Intern Med. 2020, 21:001560. 10.11890/jcrep.2020.001560

37. Choy B, Burns K: Simultaneous decompressive craniectomy and caesarean section. Br J Neurosurg. 2020, 121:1-2. 10.1007/s00701-020-01355-7

38. Mebrahin S, Ortswein H, Busch M, Weih M, Einhaupl K, Masuh F: Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry. 2003, 74:814-816. 10.1136/jnnp.74.6.814

39. Aguiar de Sousa D, Canhão P, Crassard J, et al.: Safety of pregnancy after cerebral venous thrombosis: results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY study. Stroke. 2017, 48:5130-5135. 10.1161/STROKEAHA.117.018829

40. Gazigolu S, Fyshoglu I, Yildirim A, Aydin CO, Allogio Z: Cerebral venous sinus thrombosis: clinical features, long-term outcome and recanalization. J Clin Neurosci. 2017, 45:248-251. 10.1016/j.jocn.2017.07.028

41. Palazzo P, Agius P, Ingrao P, et al.: Venous thrombotic recurrence after cerebral vein and dural sinus thrombosis: a long-term follow-up study. Stroke. 2017, 48:521-526. 10.1161/STROKEAHA.116.015294

42. Söyer B, Rusca M, Lukaszwiecz AC, et al.: Outcome of a cohort of severe cerebral venous thrombosis in intensive care. Ann Intensive Care. 2016, 6:29. 10.1186/s13643-016-0125-7

43. Ferro JM, Crassard J, Coutinho JM, et al.: Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. 2011, 42:2825-2831. 10.1161/STROKEAHA.111.615395

44. Karsy M, Harmer JR, Guan J, et al.: Outcomes in adults with cerebral venous sinus thrombosis: a retrospective cohort study. J Clin Neurosci. 2018, 53:34-40. 10.1016/j.jocn.2018.05.004

45. Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M: Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome. Clin Neuroradiol Neurosurg. 2005, 107:99-107. 10.1007/s00701-004-006.002

46. Ferro JM, Canhão P, Stam J, et al.: Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. Stroke. 2009, 40:3133-3138. 10.1161/STROKEAHA.109.553891

47. Kowill CM, Kaminski J, Weir V, et al.: Severe cerebral venous and sinus thrombosis: clinical course, imaging correlates, and prognosis. Neurocrit Care. 2016, 25:392-400. 10.1007/s12028-016-0236-8

48. Koopman K, Uttenhoogaart M, Vootman PC, van der Meer J, De Keyser J, Luijckx GJ: Long-term sequelae
after cerebral venous thrombosis in functionally independent patients. J Stroke Cerebrovasc Dis. 2009, 18:198-202. 10.1016/j.jstrokecerebrovasdis.2008.10.004